Statements (34)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
gptkb:drug |
| gptkbp:approvalYear |
2001
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
G03AC09
|
| gptkbp:bioavailability |
76%
|
| gptkbp:CASNumber |
67392-87-4
|
| gptkbp:contraindication |
renal impairment
adrenal insufficiency hepatic impairment |
| gptkbp:discoveredBy |
gptkb:Schering_AG
|
| gptkbp:drugClass |
progestin
antiandrogen antimineralocorticoid |
| gptkbp:eliminationHalfLife |
30 hours
|
| gptkbp:excretion |
urine
feces |
| gptkbp:fullName |
gptkb:drospirenone
|
| gptkbp:hasMolecularFormula |
C24H30O3
|
| https://www.w3.org/2000/01/rdf-schema#label |
DRSP
|
| gptkbp:marketedAs |
gptkb:Angeliq
gptkb:Yaz gptkb:Yasmin |
| gptkbp:metabolism |
liver
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
headache breast tenderness thromboembolism hyperkalemia |
| gptkbp:usedIn |
hormone replacement therapy
oral contraceptives |
| gptkbp:bfsParent |
gptkb:drospirenone
|
| gptkbp:bfsLayer |
7
|